Abstract:Abstract Background: Hypoxia inducible factor-1α (HIF-1α) is a therapeutic target in solid tumors because it activates transcription of the genes associated with tumor growth, angiogenesis and chemo/radio-resistance. Activation of PPARα has been demonstrated to inhibit tumor growth and angiogenesis, yet the mechanisms behind these actions remain obscure. The present study examined the effects of PPARα activation on HIF-1α mediated signaling in human cancer cells. Methods: The human cancer lines MCF-7 (breast) and A2780 (ovarian), and human endothelial line, EA.hy926 were used as model systems for this study. Hypoxia was achieved via a hypoxia chamber. The HRE-luciferase reporter gene and Western blot were applied to analyze HIF-1α expression and activity. RT-PCR and co-immunoprecipitation were performed to understand the molecular mechanisms of PPARα-mediated suppression of HIF-1α signaling. The level of vascular endothelial growth factor (VEGF) in cultured medium was determined using an ELISA, and in vitro angiogenesis was evaluated using the tube formation assay. Results: Incubation of cancer cells with 1 % oxygen for 16 hours significantly induced HIF-1α expression and activity. Treatment of the cells with PPARα agonists, but not a PPARγ agonist, prior to hypoxia diminished hypoxia-induced HIF-1α expression and activity. Consistently, a PPARα antagonist attenuated PPARα agonist-induced suppression of HIF-1α signaling. Over-expression of an HA-tagged HIF-1α and HIF-1α-P402/P564A mutant protein demonstrated that activation of PPARα promotes HIF-1 α degradation in our model system. This was further confirmed by the use of MG-132, a proteasome inhibitor, which reversed PPARα-mediated suppression of the HIF-1α signaling, and by RT-PCR analysis of HIF-1α mRNA, which was unchanged by PPARα activation. Using the co-immunoprecipitation technique, we found that activation of PPARα enhances the binding of hydroxylated HIF-1α to the Von Hippel-Lindau tumor suppressor, a protein known to mediate HIF-1α degradation through the ubiquitin-proteasome pathway. Consequential to the PPARα-mediated suppression of HIF-1α signaling, vascular endothelial growth factor secretion from cancer cells was found to be significantly reduced, and the tube formation by EA.hy926 cells was dramatically impaired. Summary: Activation of PPARα suppresses HIF-1α expression and activity by promoting HIF-1α degradation in cancer cells. PPARα agonists are potential anticancer agents that inhibit tumor angiogenesis via the suppression of HIF-1α signaling. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B7.

Abstract 2795: MARVELD1 Regulates Hypoxia-Induced Oxidative Stress Response and Tumor Growth

MARVELD1 interacting with catalase regulates reactive oxygen species metabolism and mediates the sensitivity to chemotherapeutic drugs in epithelial tumors of the reproductive system.

Abstract 365: Autocrine Vascular Endothelial Growth Factor Signaling Mediates Survival and Chemoresistance of Human Colorectal Cancer Cells

MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma.

Abstract A001: Colorectal Cancer Cell-Derived Exosomes Containing Mir-183-5p Regulate Angiogenesis Via FOXO1

Biological and Clinical Significance of Epigenetic Silencing of MARVELD1 Gene in Lung Cancer

Identification and Characterization of MARVELD1, a Novel Nuclear Protein That is Down-Regulated in Multiple Cancers and Silenced by DNA Methylation.

Hypoxia induces ROS-resistant memory upon reoxygenation in vivo promoting metastasis in part via MUC1-C

Marveld1 Modulates Cell Surface Morphology and Suppresses Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

Up-regulation of MARVEL Domain-Containing Protein 1 (MARVELD1) Accelerated the Malignant Phenotype of Glioma Cancer Cells Via Mediating JAK/STAT Signaling Pathway.

Abstract 122: 15-Lipoxygenase-1 Regulation of HIF-1a and Angiogenesis

Ras Homolog Gene Family, Member A Promotes P53 Degradation and Vascular Endothelial Growth Factor-Dependent Angiogenesis Through an Interaction with Murine Double Minute 2 under Hypoxic Conditions

Abstract 3986: MicroRNA-155 Regulates Angiogenesis by Targeting Von Hippel-Lindau (VHL) Tumor Suppressor

Melatonin Restricts the Viability and Angiogenesis of Vascular Endothelial Cells by Suppressing HIF-1α/ROS/VEGF

Abstract B7: Activation of PPARα Suppresses HIF-1α Signaling in Human Cancer Cells.

The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions

Vitamin D Modulation of Mitochondrial Oxidative Metabolism and mTOR Enforces Stress Adaptations and Anticancer Responses

Abstract 1993: Gluthathione Peroxidase 2 Downregulation in the PyMT Mammary Tumor Model Leads to an Aggressive Phenotype Due to Stimulation of Angiogenesis and Tumor Stemness Via HIF1 Alpha Signaling

Abstract SY31-02: Determinants of hypoxia in pancreatic cancer and identification of ULK1 as a potential therapeutic target

ROR Suppresses Cancer-Associated Inflammation by Repressing Respiratory Complex I-Dependent ROS Generation